RRC ID 62264
Author Amagai Y, Fujiyuki T, Yoneda M, Shoji K, Furukawa Y, Sato H, Kai C.
Title Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells.
Journal Sci Rep
Abstract Oncolytic virotherapy is a distinctive antitumor therapy based on the cancer-cell-specific infectivity and killing activity of viruses, which exert a considerable antitumor effect with only a few treatments. Because colorectal cancer cells often acquire resistance to the molecular-targeted therapies and alternative treatments are called for, in this study, we evaluated the oncolytic activity against colorectal cancer cells of a recombinant measles virus (rMV-SLAMblind), which is blind to signaling lymphocytic activation molecule (SLAM) and infects target cells via nectin-4/poliovirus receptor-related 4 protein. We examined 10 cell lines including 8 cell lines that were resistant to epidermal-growth-factor-receptor (EGFR) targeted therapy. rMV-SLAMblind infected and lysed the nectin-4-positive cell lines dependently on nectin-4 expression, in spite of mutation in EGFR cascade. Tumour progression in xenograft models was also abrogated by the virus, and the infection of cancer cells in vivo by the virus was demonstrated with both flow cytometry and a histological analysis. Therefore, rMV-SLAMblind is considered a novel therapeutic agent for colorectal cancers, including those resistant to molecular-targeted therapies.
Volume 6
Pages 24572
Published 2016-4-19
DOI 10.1038/srep24572
PII srep24572
PMID 27090874
PMC PMC4835780
MeSH Animals Cell Line, Tumor Chlorocebus aethiops Colorectal Neoplasms / therapy* Colorectal Neoplasms / virology Green Fluorescent Proteins Humans Interleukin-1 / genetics* Interleukin-1 / metabolism Lymphocyte Activation / genetics Measles virus / genetics* Oncolytic Virotherapy Oncolytic Viruses* Vero Cells Xenograft Model Antitumor Assays
IF 3.998
Human and Animal Cells MCF7(RCB1904)